| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164592P | 2021-03-23 | 2021-03-23 |
| Publication Number | Publication Date |
|---|---|
| AR125079A1true AR125079A1 (en) | 2023-06-07 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100581AAR125079A1 (en) | 2021-03-23 | 2022-03-14 | CARBOXY-SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS |
| Country | Link |
|---|---|
| US (2) | US11618767B2 (en) |
| EP (1) | EP4314004B1 (en) |
| JP (1) | JP7598484B2 (en) |
| KR (1) | KR20230148222A (en) |
| CN (1) | CN116888137B (en) |
| AR (1) | AR125079A1 (en) |
| AU (1) | AU2022245209B2 (en) |
| BR (1) | BR112023016268A2 (en) |
| CA (1) | CA3212778A1 (en) |
| ES (1) | ES3017809T3 (en) |
| IL (1) | IL305241A (en) |
| MX (1) | MX2023011280A (en) |
| TW (1) | TWI837613B (en) |
| WO (1) | WO2022204099A1 (en) |
| ZA (1) | ZA202307999B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4393937A1 (en)* | 2021-08-26 | 2024-07-03 | Duality Biologics (Suzhou) Co., Ltd. | Steroid compound and conjugate thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101227912A (en) | 2005-06-14 | 2008-07-23 | 基利得科学公司 | Substituted phenylphosphates as mutual prodrugs of steroids and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction |
| KR101295998B1 (en) | 2007-11-30 | 2013-08-13 | 화이자 리미티드 | Novel glucocorticoid receptor agonists |
| WO2009085879A2 (en) | 2007-12-21 | 2009-07-09 | Schering Corporation | C20-c21 substituted glucocorticoid receptor agonists |
| US20110294766A1 (en) | 2008-02-27 | 2011-12-01 | Astrazeneca Ab | 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use |
| EP3359194A4 (en) | 2015-10-06 | 2019-04-24 | Merck Sharp & Dohme Corp. | ANTIBODY-MEDICINAL CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS |
| EP3407916B1 (en) | 2016-01-29 | 2023-12-20 | Merck Sharp & Dohme LLC | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| HRP20210924T1 (en)* | 2016-06-02 | 2021-09-03 | Abbvie Inc. | GLUCOCORTICOID RECEPTOR AGONIST AND ITS IMMUNOCONJUGATES |
| WO2018089373A2 (en)* | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| SI3658192T1 (en)* | 2017-12-01 | 2021-08-31 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| SG11202004865SA (en) | 2017-12-01 | 2020-06-29 | Abbvie Inc | Anti-cd40 antibody drug conjugates |
| US20230310634A1 (en) | 2020-04-22 | 2023-10-05 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
| Publication number | Publication date |
|---|---|
| CN116888137B (en) | 2025-08-26 |
| WO2022204099A1 (en) | 2022-09-29 |
| JP7598484B2 (en) | 2024-12-11 |
| JP2024510640A (en) | 2024-03-08 |
| ES3017809T3 (en) | 2025-05-13 |
| EP4314004A1 (en) | 2024-02-07 |
| US11618767B2 (en) | 2023-04-04 |
| US12162905B2 (en) | 2024-12-10 |
| IL305241A (en) | 2023-10-01 |
| CN116888137A (en) | 2023-10-13 |
| US20230227493A1 (en) | 2023-07-20 |
| BR112023016268A2 (en) | 2023-10-03 |
| CA3212778A1 (en) | 2022-09-29 |
| EP4314004B1 (en) | 2025-01-22 |
| KR20230148222A (en) | 2023-10-24 |
| TW202304463A (en) | 2023-02-01 |
| AU2022245209A1 (en) | 2023-09-07 |
| MX2023011280A (en) | 2023-10-04 |
| ZA202307999B (en) | 2025-02-26 |
| AU2022245209B2 (en) | 2024-03-07 |
| US20220306681A1 (en) | 2022-09-29 |
| TWI837613B (en) | 2024-04-01 |
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011279A (en) | GLUCOCORTICOID RECEPTOR AGONISTS. | |
| CO2021008776A2 (en) | Il-17a inhibitors | |
| AR125079A1 (en) | CARBOXY-SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | |
| EA202191381A1 (en) | IMPROVED SYNTHESIS OF KEY INTERMEDIATE JOINT TO OBTAIN A JOINT REPRESENTING A G12C KRAS INHIBITOR | |
| MA64510B1 (en) | Glp-1 receptor agonists and their uses | |
| AR129635A2 (en) | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | |
| CL2022001258A1 (en) | Improved synthesis of kras g12c inhibitor compound | |
| JP2020519664A5 (en) | ||
| PE20190409A1 (en) | HETEROCYCLIC COMPOUND | |
| AR081204A1 (en) | PIRROLOPIRAZINAS AS QUINASE INHIBITORS | |
| MY185837A (en) | Heteroaryl syk inhibitors | |
| AR107032A1 (en) | PAD4 BICYCLIC INHIBITORS | |
| EA201890695A1 (en) | NEW PYRAZOLYL SUBSTITUTED HETEROARYLES AND THEIR APPLICATION AS MEDICINES | |
| PE20190806A1 (en) | HETEROCYCLIC AGONISTS OF THE APELINE RECEPTOR (JPA) AND USES OF THEM | |
| WO2014125426A1 (en) | Trisubstituted heterocyclic derivatives as ror gamma modulators | |
| PE20170083A1 (en) | NEW COMPOUNDS | |
| PE20181020A1 (en) | MUCLEAR RECEIVER MODULATORS | |
| AR106522A1 (en) | INTERMEDIARIES TO PREPARE PIRIDAZINONE HERBICIDES, AND A PROCESS TO PREPARE THEM | |
| PE20221034A1 (en) | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | |
| SI3102573T1 (en) | Substituted thiazole or oxazole p2x7 receptor antagonists | |
| MX2021012743A (en) | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use. | |
| AR122929A1 (en) | NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| MX355996B (en) | Isoxazolines as therapeutic agents. | |
| PL4192882T3 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| PE20211088A1 (en) | ISOXAZOLINE COMPOUNDS TO CONTROL INVERTEBRATE PESTS |